Lifeloc Revenue Plunges 25% Amidst Broad Sales Decline

TL;DR

**LCTC's revenue is in freefall, signaling deep trouble ahead; sell now.**

AI Summary

Lifeloc Technologies, Inc. reported a significant decline in revenue for the three months ended June 30, 2025, with total revenue decreasing by 24.9% to $1,470,000 from $1,960,000 in the prior-year period. Product sales, the primary revenue driver, fell by 25.5% to $1,390,000 from $1,865,000. Royalties also saw a substantial drop of 33.3% to $20,000 from $30,000, while rentals decreased by 12.5% to $60,000 from $65,000. For the six months ended June 30, 2025, total revenue decreased by 19.3% to $3,000,000 from $3,720,000. The company's net income was not explicitly stated in the provided data, but the revenue decline suggests potential pressure on profitability. Key business changes include the issuance of warrants in connection with a subordinated debenture and term loan, impacting the company's capital structure. Risks include the ongoing revenue decline and the financial obligations associated with the debenture and term loan. The strategic outlook appears challenged given the consistent revenue contraction across all segments.

Why It Matters

This significant revenue decline of 24.9% for Lifeloc Technologies, Inc. signals potential operational challenges and could negatively impact investor confidence, leading to a decrease in stock value. For employees, sustained revenue drops might foreshadow cost-cutting measures or job insecurity. Customers could face reduced product development or support if financial pressures mount. In the competitive landscape of laboratory analytical instruments, a shrinking revenue base makes it harder for Lifeloc to invest in innovation and maintain market share against larger, more stable competitors.

Risk Assessment

Risk Level: high — The company faces a high risk level due to a substantial 24.9% decrease in total revenue for the quarter ended June 30, 2025, and a 19.3% decrease for the six months ended June 30, 2025. This consistent and significant decline across all revenue segments (product sales, royalties, and rentals) indicates fundamental business challenges and potential profitability issues, evidenced by product sales dropping 25.5% to $1,390,000.

Analyst Insight

Investors should consider divesting from Lifeloc Technologies, Inc. given the consistent and significant revenue declines across all segments. The company's inability to grow its top line suggests underlying operational issues that could further erode shareholder value.

Financial Highlights

revenue

$1,470,000

revenue Growth

-24.9%

Revenue Breakdown

Key Numbers

• $1.47M — Total Revenue (Q2 2025) (Decreased by 24.9% from $1.96M in Q2 2024)
• $1.39M — Product Sales (Q2 2025) (Fell by 25.5% from $1.865M in Q2 2024)
• $3.00M — Total Revenue (YTD 2025) (Decreased by 19.3% from $3.72M in YTD 2024)
• 24.9% — Quarterly Revenue Decrease (Percentage decline in total revenue for Q2 2025 compared to Q2 2024)
• 19.3% — Year-to-Date Revenue Decrease (Percentage decline in total revenue for the six months ended June 30, 2025, compared to the prior year)

Key Players & Entities

• Lifeloc Technologies, Inc. (company) — filer of the 10-Q
• $1,470,000 (dollar_amount) — total revenue for Q2 2025
• $1,960,000 (dollar_amount) — total revenue for Q2 2024
• $1,390,000 (dollar_amount) — product sales for Q2 2025
• $1,865,000 (dollar_amount) — product sales for Q2 2024
• $20,000 (dollar_amount) — royalties for Q2 2025
• $30,000 (dollar_amount) — royalties for Q2 2024
• $60,000 (dollar_amount) — rentals for Q2 2025
• $65,000 (dollar_amount) — rentals for Q2 2024
• EDCO Partners LLLP (company) — holder of subordinated debenture

FAQ

Risk Factors

• Revenue Decline [high — financial]: Total revenue decreased by 24.9% in Q2 2025 to $1,470,000 from $1,960,000 in Q2 2024. This trend continued for the six months ended June 30, 2025, with revenue down 19.3% to $3,000,000 from $3,720,000.
• Debt Obligations [medium — financial]: The company has financial obligations related to a subordinated debenture and a term loan. The issuance of warrants in connection with these instruments adds complexity to the capital structure.
• Competitive Landscape [medium — market]: As a company in the laboratory analytical instruments sector, Lifeloc Technologies faces competition that could impact its market share and pricing power, especially amidst a revenue downturn.
• Dependence on Product Sales [high — operational]: Product sales constitute the largest portion of revenue, falling 25.5% in Q2 2025. A continued decline in this segment poses a significant risk to overall financial performance.

Industry Context

Lifeloc Technologies operates in the laboratory analytical instruments sector, which is characterized by technological innovation and regulatory compliance. The industry often serves niche markets, such as law enforcement and workplace safety, where accuracy and reliability are paramount. Trends include the development of portable and connected devices, as well as increasing demand for data analytics related to testing.

Regulatory Implications

Companies in the analytical instrument sector, particularly those serving safety and compliance markets, are subject to stringent quality control and performance standards. Lifeloc Technologies' products likely adhere to specific certifications and regulations, requiring ongoing investment in compliance and product validation.

What Investors Should Do

1. Monitor revenue trends closely
2. Analyze the impact of debt financing
3. Evaluate product pipeline and market strategy

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing a significant revenue decline.
• 2025-08-11: Filing Date of 10-Q — Indicates the official release of financial and operational information for the period ending June 30, 2025.
• 2025-02-28: Subordinated Debenture Issuance — A key event impacting the company's capital structure and future financial obligations.

Glossary

Subordinated Debenture

A type of debt that ranks below other, more senior debt but above equity in the event of liquidation. (Represents a significant financial obligation for Lifeloc Technologies, impacting its debt structure.)

Warrants

Securities that give the holder the right, but not the obligation, to purchase a company's stock at a predetermined price. (Issued in connection with debt, these can dilute existing shareholders if exercised and add to future capital structure considerations.)

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This filing details Lifeloc Technologies' financial results and operational status for the second quarter of 2025.)

Year-Over-Year Comparison

Compared to the prior year's second quarter, Lifeloc Technologies experienced a significant revenue contraction of 24.9%, driven by declines in all major segments, particularly product sales. This revenue downturn suggests potential pressure on profitability and margins, although specific net income figures are not detailed here. New financial instruments, including a subordinated debenture and term loan with associated warrants, have been introduced, altering the company's capital structure and introducing new financial obligations.

Filing Documents

• lctc_10q-063025.htm (10-Q) — 776KB
• ex31x1.htm (EX-31.1) — 8KB
• ex31x2.htm (EX-31.2) — 8KB
• ex32x1.htm (EX-32.1) — 5KB
• ex32x2.htm (EX-32.2) — 4KB
• 0001079973-25-001237.txt ( ) — 4227KB
• lctc-20250630.xsd (EX-101.SCH) — 30KB
• lctc-20250630_cal.xml (EX-101.CAL) — 48KB
• lctc-20250630_def.xml (EX-101.DEF) — 88KB
• lctc-20250630_lab.xml (EX-101.LAB) — 262KB
• lctc-20250630_pre.xml (EX-101.PRE) — 213KB
• lctc_10q-063025_htm.xml (XML) — 673KB

FINANCIAL STATEMENTS (UNAUDITED)

FINANCIAL STATEMENTS (UNAUDITED) Condensed Balance Sheets as of June 30, 2025 and December 31, 2024 (Unaudited) 3 Condensed Statements of Income (Loss) (Unaudited) for the three and six months ended June 30, 2025 and June 30, 2024 4 Condensed Statements of Changes in Stockholders' Equity (Unaudited) for the three and six months ended June 30, 2025 and 2024 6 Condensed Statements of Cash Flows (Unaudited) for the six months ended June 30, 2025 and 2024 7 Notes to Condensed Financial Statements (Unaudited) 8 ITEM 2

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 17 ITEM 3

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 23 ITEM 4

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 23 PART II. OTHER INFORMATION 24 ITEM 1

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 24 ITEM 1A

RISK FACTORS

RISK FACTORS 24 ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 24 ITEM 3 DEFAULTS UPON SENIOR SECURITIES 24 ITEM 4 MINE SAFETY DISCLOSURES 24 ITEM 5 OTHER INFORMATION 24 ITEM 6 EXHIBITS 25

FINANCIAL

PART I FINANCIAL INFORMATION

– FINANCIAL STATEMENTS

ITEM 1 – FINANCIAL STATEMENTS LIFELOC TECHNOLOGIES, INC. Condensed Balance Sheets (Unaudited) ASSETS June 30, 2025 December 31, 2024 CURRENT ASSETS: Cash and cash equivalents $ 995,750 $ 1,243,746 Accounts receivable, net 765,730 732,541 Inventories, net 2,988,752 2,996,397 Federal and state income taxes receivable 55,531 80,560 Prepaid expenses and other 160,079 40,045 Total current assets 4,965,842 5,093,289 PROPERTY, PLANT AND EQUIPMENT: Land 317,932 317,932 Building 1,928,795 1,928,795 Real-time Alcohol Detection And Recognition equipment and software 569,448 569,448 Production equipment, software and space modifications 1,349,839 1,349,839 Training courses 432,375 432,375 Office equipment, software and space modifications 254,333 254,333 Sales and marketing equipment and space modifications 231,818 226,356 Research and development equipment, software and space modifications 805,012 787,664 Research and development equipment, software and space modifications not in service 347,448 128,007 Less accumulated depreciation ( 3,826,061 ) ( 3,613,452 ) Total property and equipment, net 2,410,939 2,381,297 OTHER ASSETS: Patents, net 74,913 78,723 Deposits and other 12,261 12,261 Deferred income taxes 1,159,199 1,159,199 Total other assets 1,246,373 1,250,183 Total assets $ 8,623,154 $ 8,724,769 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 393,046 $ 251,627 Term loan payable, current portion 54,016 53,195 Subordinated debentures payable, current portion 16,645 — Customer and tenant deposits 37,628 43,814 Accrued expenses 349,397 293,981 Deferred revenue, current portion 58,862 54,458 Product warranty reserve 46,500 46,500 Total current liabilities 956,094 743,575 TERM LOAN PAYABLE, net of current portion and debt issuance costs 1,086,062 1,119,152 SUBORDINATED DEBENTURES PAYABLE, net of current port

View Full Filing

View this 10-Q filing on SEC EDGAR